Representativeness in randomised clinical trials supporting acute coronary syndrome guidelines
Authors' conclusion
Randomised clinical trials supporting CPGs for ACS are not fully representative of the diversity of the ACS population and their current standard of care.
Study context
- Population
- Randomised Clinical Trials (RCTs) cited in American and European Clinical Practice Guidelines (CPGs) for ST- and non-ST-elevation Acute Coronary Syndrome (ACS)
- Participants
- 407 primary RCT publications
- Outcome
- Representativeness and standard of care of RCTs supporting ACS CPGs
Pooled result
As reported in the abstract
Representativeness of RCTs
- RCTs recruiting in North America
- 52.6
- RCTs recruiting in Europe
- 73.2%
- RCTs recruiting in Asia
- 25.3%
- RCTs enrolling patients with ACS
- 68.6%
- RCTs enrolling no patients with ACS
- 31.4%
- Female patients
- 29.9%
- Non-white patients
- <20%
- Patients undergoing percutaneous coronary intervention (PCI) among all RCTs
- 42.7%
- STEMI: fibrinolysis vs primary PCI participants
- 3.3-fold higher
- All-cause mortality in RCTs with follow-up ≤ 1 year
- 11.9%
Original publication
Representativeness in randomised clinical trials supporting acute coronary syndrome guidelines. Eur Heart J Qual Care Clin Outcomes. Published 25 January 2023. doi:10.
Summarised from the published abstract; every number is checked against it